Clinical Trials Browser

Phase 1/2 × Burkitt Lymphoma × 30 days × Clear all

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06395103 2026-04-13

MK-9999-01A

Phase 1/2 Recruiting

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT07069699 2026-04-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1/2 Recruiting

50 enrolled

Lymphoid

Burkitt Lymphoma

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

96 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04404660 2026-04-08

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Phase 1/2 Active not recruiting

153 enrolled 3 FDA

Lymphoid

Burkitt Lymphoma, Recurrence

NCT07109219 2026-04-06

ALLight

Phase 1/2 Recruiting

83 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03504644 2026-04-02

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

40 enrolled 18 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03223610 2026-04-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Phase 1/2 Recruiting

32 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

104 enrolled

Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05674175 2026-03-27

Co-administration of CART22-65s and huCART19 for B-ALL

Phase 1/2 Recruiting

93 enrolled

Lymphoid

Burkitt Lymphoma